Sökning: WFRF:(Jensen Jørgen Skov) >
In vitro activity o...
-
Jensen, Jørgen SkovDepartment of Bacteria, Parasites and Fungi, Research Unit for Reproductive Tract Microbiology, Statens Serum Institut, Copenhagen, Denmark
(författare)
In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
2020-06-18
-
Taylor & Francis,2020
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-84961
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-84961URI
-
https://doi.org/10.1080/22221751.2020.1775498DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies:GlaxoSmithKlineFederal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under OTA Agreement HHSO100201300011C
-
Mycoplasma genitalium has developed resistance to first-line azithromycin and second-line moxifloxacin. Third-line pristinamycin is only 75% effective. Gepotidacin, a novel triazaacenaphthylene topoisomerase II inhibitor, blocks bacterial DNA replication. We determined thein vitroactivity of gepotidacin alone and in combination with doxycycline against a diverse collection of Mycoplasma genitalium isolates (n = 54).Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined by a Vero-cell culture method. Macrolide resistance was present in 31 (57%) isolates, fluoroquinolone resistance in 18 (33%) isolates, and 17 (31%) had dual resistance. Synergy testing was performed for gepotidacin and doxycycline by checkerboard analysis for two macrolide- and two dual-resistant isolates.Gepotidacin was active against all 54 M. genitalium isolates with median and modal MICs of 0.125 mg/L and MIC(90)of 0.25 mg/L (range <= 0.016-0.5 mg/L). No difference in gepotidacin MIC between macrolide-resistant and -susceptible isolates (p = 0.24) or between fluoroquinolone-, dual-resistant and -susceptible isolates (p = 0.2) was demonstrated. Gepotidacin MBCs were available for 44 M. genitalium isolates with median MIC of 0.064 mg/L and median MBC of 0.125 mg/L. All isolates had <= 4-fold difference between MIC and MBC, suggesting bactericidal effect for gepotidacin. Checkerboard analysis indicated synergistic effect for gepotidacin in combination with doxycycline [fractional inhibitory concentration index (sigma FICI) of 0.5] for two isolates and additive/indifference (sigma FICI at 0.62 and 0.75) for two isolates.Gepotidacin warrants further evaluation in clinical treatment trials for M. genitalium. Combination therapy with doxycycline should be clinically studied to assess effect and potential protection against development and/or spread of gepotidacin resistance.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Nørgaard, ChristinaDepartment of Bacteria, Parasites and Fungi, Research Unit for Reproductive Tract Microbiology, Statens Serum Institut, Copenhagen, Denmark
(författare)
-
Scangarella-Oman, NicoleGlaxoSmithKline, Collegeville Pennsylvania, USA
(författare)
-
Unemo, Magnus,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län(Swepub:oru)muo
(författare)
-
Department of Bacteria, Parasites and Fungi, Research Unit for Reproductive Tract Microbiology, Statens Serum Institut, Copenhagen, DenmarkGlaxoSmithKline, Collegeville Pennsylvania, USA
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Emerging Microbes & Infections: Taylor & Francis9:1, s. 1388-13922222-1751
Internetlänk
Hitta via bibliotek
Till lärosätets databas